USP25 and cancer: CT1113 can reduce c‐MYC levels and inhibit USP28 and USP25 in various cancer cell lines, resulting in decreased expression of MYC–MAX target genes and increased ubiquitination of substrates like c‐MYC and Tankyrase, thus exhibiting a broad‐spectrum anticancer activity.443